In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship - Mendel, D B; Laird, A D; Xin, X (Clin Cancer Res, 2003)
et al.